Lenalidomide Grindeks (Lenalidomide)

Lenalidomide binds to the cereblon component of the CRL4‑CRBN E3 ubiquitin ligase complex, altering its substrate specificity. This triggers ubiquitination and degradation of transcription factors Ikaros and Aiolos, leading to anti‑angiogenic, immunomodulatory, and anti‑proliferative effects that suppress malignant cell growth.

The dosing regimen for lenalidomide is individualized and set by the prescribing clinician based on the specific indication, disease stage, renal function, and patient tolerance. Healthcare providers determine the appropriate strength, schedule, and any dose adjustments needed.

Lenalidomide is classified as Pregnancy Category X, meaning it is contraindicated during pregnancy due to a high risk of fetal harm. It is also not recommended for breastfeeding mothers because it can be excreted in breast milk and may affect the infant.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and the necessary import documentation.

Lenalidomide is a second‑generation immunomodulatory imide drug (IMiD) that offers greater potency and a more favorable safety profile compared with thalidomide, the first‑generation IMiD. Compared with proteasome inhibitors, lenalidomide provides oral administration and distinct immunomodulatory effects, making it a valuable option in combination regimens.

Store Lenalidomide Grindeks at temperatures below 25 °C in its original packaging. Protect the product from moisture, excessive heat, and direct sunlight. Keep the container tightly closed and out of reach of children to maintain stability and potency.

Lenalidomide Grindeks is taken orally, usually with or without food, as directed by the prescribing physician. The tablets are swallowed whole with a glass of water. Patients should follow the exact schedule and any special instructions provided by their healthcare professional.

Serious risks include venous thromboembolism, severe neutropenia or thrombocytopenia, secondary primary malignancies, and significant liver toxicity. Patients should be monitored closely for signs of clotting, infections, abnormal bleeding, and liver function changes throughout therapy.

Lenalidomide Grindeks should not be used by pregnant women, individuals with known hypersensitivity to lenalidomide or its excipients, and patients with uncontrolled severe infections. Caution is also advised for those with significant renal impairment or a history of thromboembolic events, pending physician assessment.